Edwards Lifesciences (EW) EBT (2009 - 2026)

Edwards Lifesciences has reported EBT for 18 years, with the latest figure at $459.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 5.78% year-over-year to $459.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (down 19.42% YoY), and the FY2025 full-year result was $1.3 billion, down 17.78% from the prior year.
• EBT for Q1 2026 stood at $459.0 million, up from $90.4 million in the prior quarter.
• The five-year high for EBT was $464.7 million in Q2 2022, with the low at $90.4 million in Q4 2025.
• Average EBT over 5 years is $366.4 million, with a median of $390.1 million recorded in 2024.
• Year-over-year, EBT surged 73.7% in 2023 and tumbled 76.83% in 2025.
• Tracing EW's EBT over 5 years: stood at $211.4 million in 2022, then jumped by 73.7% to $367.2 million in 2023, then rose by 6.24% to $390.1 million in 2024, then plunged by 76.83% to $90.4 million in 2025, then soared by 407.74% to $459.0 million in 2026.
• The last three EBT figures came in at $459.0 million (Q1 2026), $90.4 million (Q4 2025), and $348.4 million (Q3 2025), per Business Quant data.

Peer Comparison